These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19309554)

  • 1. Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.
    Secchiero P; Sblattero D; Chiaruttini C; Melloni E; Macor P; Zorzet S; Tripodo C; Tedesco F; Marzari R; Zauli G
    Int J Immunopathol Pharmacol; 2009; 22(1):73-83. PubMed ID: 19309554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.
    Dobson CL; Main S; Newton P; Chodorge M; Cadwallader K; Humphreys R; Albert V; Vaughan TJ; Minter RR; Edwards BM
    MAbs; 2009; 1(6):552-62. PubMed ID: 20068388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death.
    Chen L; Qiu Y; Hao Z; Cai J; Zhang S; Liu Y; Zheng D
    IUBMB Life; 2017 Sep; 69(9):735-744. PubMed ID: 28748573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
    Secchiero P; Zauli G
    Curr Opin Hematol; 2008 Jan; 15(1):42-8. PubMed ID: 18043245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.
    Tamada T; Shinmi D; Ikeda M; Yonezawa Y; Kataoka S; Kuroki R; Mori E; Motoki K
    Sci Rep; 2015 Dec; 5():17936. PubMed ID: 26672965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
    Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
    Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.
    Szliszka E; Mazur B; Zydowicz G; Czuba ZP; Król W
    Folia Histochem Cytobiol; 2009; 47(4):579-85. PubMed ID: 20430723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity.
    Lee SH; Park DW; Sung ES; Park HR; Kim JK; Kim YS
    Mol Immunol; 2010 Jan; 47(4):816-24. PubMed ID: 19864027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.
    Zauli G; Corallini F; Zorzet S; Grill V; Marzari R; Secchiero P
    Invest New Drugs; 2012 Feb; 30(1):405-7. PubMed ID: 20714918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
    Natoni A; MacFarlane M; Inoue S; Walewska R; Majid A; Knee D; Stover DR; Dyer MJ; Cohen GM
    Br J Haematol; 2007 Nov; 139(4):568-77. PubMed ID: 17922877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
    Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
    Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
    MacFarlane M; Inoue S; Kohlhaas SL; Majid A; Harper N; Kennedy DB; Dyer MJ; Cohen GM
    Cell Death Differ; 2005 Jul; 12(7):773-82. PubMed ID: 15861184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue distribution of the death ligand TRAIL and its receptors.
    Spierings DC; de Vries EG; Vellenga E; van den Heuvel FA; Koornstra JJ; Wesseling J; Hollema H; de Jong S
    J Histochem Cytochem; 2004 Jun; 52(6):821-31. PubMed ID: 15150291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
    Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
    Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAD001 (everolimus) enhances TRAIL cytotoxicity in human leukemic Jurkat T cells by upregulating DR5.
    Lee MW; Kim DS; Eom JE; Ko YJ; Sung KW; Koo HH; Yoo KH
    Biochem Biophys Res Commun; 2015 Aug; 463(4):894-9. PubMed ID: 26074143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal activity induces caspase- and mitochondrial-dependent apoptosis in human leukemia Jurkat cells.
    Du YW; Chen JG; Bai HL; Huang HY; Wang J; Li SL; Liu GC; Jiang Q; Chai J; Zhao YP; Ma YF
    Cancer Biother Radiopharm; 2011 Apr; 26(2):143-52. PubMed ID: 21539448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.